Literature DB >> 31598399

DWI and DCE-MRI approaches for differentiating reversibly electroporated penumbra from irreversibly electroporated ablation zones in a rabbit liver model.

Anna J Shangguan1,2, Chong Sun1,3, Bin Wang1,4, Liang Pan1,5, Quanhong Ma1, Su Hu1,6, Jia Yang1, Aydin Eresen1, Yuri Velichko1, Vahid Yaghmai1, Zhuoli Zhang1.   

Abstract

The purpose of our study was to investigate the hypothesis that DWI-MRI and DCE-MRI cab be used to distinguish between IRE and RE zones of IRE treatment in a rabbit liver model. 6 rabbits underwent baseline and post-procedure MR imaging with DWI and DCE-MRI as well as IRE (10 pulses, 2000 V, 10 µs/pulse, 10 ms between pulses). Rabbits were euthanized immediately after post-procedure MRI to acquire liver tissue for histology. Liver tissues were fixed and then stained with HE and TUNEL. T1w and T2w intensities in different treatment zones were calculated and normalized to paraspinal muscle signal. ADC maps were generated from DWI. AUC, PE, TTP, WIS, Ktrans, Kep, and VE were calculated from DCE-MRI. Apoptosis index was calculated from TUNEL stained tissues. P<0.05 was considered statistically significant. Entire IRE treated region was hyperintense compared with untreated tissues on T1w, with the RE zone having a higher signal intensity. On DWI, IRE treated tissue had decreased ΔADC. The IRE zone has a lower ΔADC than the RE zone within the treated region. On DCE-MRI, IRE zone demonstrated the highest TTP and the lowest PE, WIS, Ktrans, Kep, and VE, followed by the RE zone then the untreated tissue. TUNEL staining of liver tissues showed that the IRE zone had the highest apoptosis index, followed by the RE zone and then untreated tissue. In conclusion, DCE-MRI and DWI parameters allow differentiation between RE and IRE zones in a rabbit liver model. AJCR
Copyright © 2019.

Entities:  

Keywords:  DCE-MRI; HCC; IRE; MRI; perfusion

Year:  2019        PMID: 31598399      PMCID: PMC6780669     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  33 in total

1.  MR imaging to assess immediate response to irreversible electroporation for targeted ablation of liver tissues: preclinical feasibility studies in a rodent model.

Authors:  Yue Zhang; Yang Guo; Ann B Ragin; Robert J Lewandowski; Guang-Yu Yang; Grace M Nijm; Alan V Sahakian; Reed A Omary; Andrew C Larson
Journal:  Radiology       Date:  2010-08       Impact factor: 11.105

2.  MR imaging findings of high-voltage electrical burns in the upper extremities: correlation with angiographic findings.

Authors:  Gyung Kyu Lee; Kyung Jin Suh; Ik Won Kang; Dae Hyun Hwang; Seon Jung Min; You Mie Han; Min Ho Choi
Journal:  Acta Radiol       Date:  2011-03-01       Impact factor: 1.990

3.  Dual-input two-compartment pharmacokinetic model of dynamic contrast-enhanced magnetic resonance imaging in hepatocellular carcinoma.

Authors:  Jian-Feng Yang; Zhen-Hua Zhao; Yu Zhang; Li Zhao; Li-Ming Yang; Min-Ming Zhang; Bo-Yin Wang; Ting Wang; Bao-Chun Lu
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

4.  Irreversible Electroporation: Defining the MRI Appearance of the Ablation Zone With Histopathologic Correlation in a Porcine Liver Model.

Authors:  Ely R Felker; Isabel Dregely; Dong Jin Chung; Kyunghyun Sung; Ferdnand C Osuagwu; Charles Lassman; James Sayre; Holden Wu; David S Lu
Journal:  AJR Am J Roentgenol       Date:  2017-02-08       Impact factor: 3.959

5.  Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.

Authors:  Lei Qin; Xiang Li; Amanda Stroiney; Jinrong Qu; Jeffrey Helgager; David A Reardon; Geoffrey S Young
Journal:  Neuroradiology       Date:  2017-01-09       Impact factor: 2.804

6.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

Authors:  Anwar R Padhani; Guoying Liu; Dow Mu Koh; Thomas L Chenevert; Harriet C Thoeny; Taro Takahara; Andrew Dzik-Jurasz; Brian D Ross; Marc Van Cauteren; David Collins; Dima A Hammoud; Gordon J S Rustin; Bachir Taouli; Peter L Choyke
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 7.  The state of irreversible electroporation in interventional oncology.

Authors:  Mikhail Silk; David Tahour; Govindarajan Srimathveeravalli; Stephen B Solomon; Raymond H Thornton
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

8.  Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation--what should you use and why?

Authors:  J Louis Hinshaw; Meghan G Lubner; Timothy J Ziemlewicz; Fred T Lee; Christopher L Brace
Journal:  Radiographics       Date:  2014 Sep-Oct       Impact factor: 5.333

9.  Irreversible Electroporation in Patients with Hepatocellular Carcinoma: Immediate versus Delayed Findings at MR Imaging.

Authors:  Siddharth A Padia; Guy E Johnson; Raymond S Yeung; James O Park; Daniel S Hippe; Matthew J Kogut
Journal:  Radiology       Date:  2015-11-02       Impact factor: 11.105

10.  Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors.

Authors:  C Niessen; S Thumann; L Beyer; B Pregler; J Kramer; S Lang; A Teufel; E M Jung; C Stroszczynski; P Wiggermann
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

View more
  2 in total

Review 1.  Combination of natural killer cell-based immunotherapy and irreversible electroporation for the treatment of hepatocellular carcinoma.

Authors:  Aydin Eresen; Jia Yang; Alessandro Scotti; Kejia Cai; Vahid Yaghmai; Zhuoli Zhang
Journal:  Ann Transl Med       Date:  2021-07

2.  Intraprocedural Transcatheter Intraarterial Perfusion (TRIP)-MRI for Evaluation of Irreversible Electroporation Therapy Response in a Rabbit Liver Tumor Model.

Authors:  Anna J Shangguan; Kang Zhou; Jia Yang; Aydin Eresen; Bin Wang; Chong Sun; Liang Pan; Su Hu; Ali T Khan; Samdeep K Mouli; Vahid Yaghmai; Zhuoli Zhang
Journal:  Clin Exp Gastroenterol       Date:  2020-11-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.